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Summary In squamous cell carcinoma of the head and neck (SCCHN), DNA ploidy as determined by flow cytometry (FCM) has been found
to yield prognostic information but only for tumours at oral sites. Cytogenetic findings have indicated complex karyotype to be a correlate of
poor clinical outcome. In the present study, 73 SCCHN were investigated with the two techniques. Aneuploid cell populations were identified
in 49 (67%) cases by FCM but in only 21 (29%) cases by cytogenetic analysis. The chromosome index (Cl), calculated as the mean
chromosome number divided by 46, was compared with the respective DNA index (Dl) obtained by FCM in 15 tumours, non-diploid according
to both techniques, Dl being systematically 12% higher than Cl in this subgroup. Eight (33%) of the 24 tumours diploid according to FCM had
complex karyotypes, three of the tumours being cytogenetically hypodiploid, three diploid and two non-diploid. The findings in the present
study may partly explain the low prognostic value of ploidy status as assessed by FCM that has been observed in SCCHN. In addition, we
conclude that FCM yields information of the genetic changes that is too unspecific, and that cytogenetic analysis shows a high rate of
unsuccessful investigations, thus diminishing the value of the two methods as prognostic factors in SCCHN.
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DNA ploidy determined by flow cytometry (FCM) is an estab-
lished prognostic variable in patients with various solid tumours,
e.g. breast cancer (Clark et al, 1989), in whom it has an impact on
treatment strategy. For squamous cell carcinoma of the head and
neck (SCCHN), the results have not been unequivocally conclusive
for tumours at sites other than the oral cavity, a category in which
patients with DNA diploid tumours are characterized by a better
survival rate than those with aneuploid tumours (Stell, 1991).
However, ploidy status as assessed by FCM might enable response
to a given therapy to be predicted, as non-diploid tumours have
been reported to be more sensitive than diploid tumours to
chemotherapy (Ensley et al, 1990; Tennvall et al, 1993). The
method is fast, with a high rate of successful analysis, and is thus
appropriate for daily clinical work. However, it is a crude way of
determining genetic alterations; for example small non-diploid
clones can be difficult to detect and pseudodiploid/near-diploid
tumours may yield false normal results. In some tumour types
(e.g. soft tissue sarcoma), attempts have been made to improve the
subclassification by assessing breadth and skewness of the DNA
diploidG/G, peak (Mandahl et al, 1993; Gustafson, 1994).
Chromosomal abnormalities determined by cytogenetic analysis
are established prognostic factors in patients with haematological
malignancies, in particular childhood acute lymphoblastic
leukaemia (Pui and Crist, 1992). Because of technical difficulties
in establishing short-term cultures, cytogenetic information from
solid tumours is more limited. However, data are now accumu-
lating; for SCCHN, complex karyotypes, in general, and
rearrangements ofband 11q13, in particular, have been found to be
associated with poor prognosis (Akervall et al, 1995). Cytogenetic
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banding analysis is time-consuming, but provides detailed and
reliable information about the genetic changes that have occurred.
The frequency of non-diploid tumours is lower as determined by
cytogenetic analysis (Jin et al, 1993, 1995) than as determined by
FCM (Stell, 1991), which may reflect difficulties in culturing
certain non-diploid cell populations. Problems with poorgrowth of
tumour cells, overgrowth of stromal cells and suboptimal
chromosome preparations clearly diminish the success rate.
Earlier comparisons of FCM and cytogenetic analysis in various
solid tumours, i.e. colorectal tumours, renal cell carcinoma and
malignant mesothelioma, have usually shown good correspondence
between DNA index and chromosome number (Petersen and
Friedrich, 1986; Remvikos et al, 1988a; Ljungberg et al, 1991;
Pyrhonen et al, 1992), although some discrepancies have also been
noted (Smeets et al, 1987; Remvikos et al, 1988b; Wolman et al,
1988; El-Naggar andPathak, 1992). Furthermore, it has been shown
that a large proportion of flow cytometrically diploid tumours have
karyotype abnormalities when analysed cytogenetically (Cabanillas
etal, 1986; Smeets etal, 1987; Breitkreutz et al, 1993; Laquerriere et
al, 1993; Mandahl et al, 1993; Matsuyama et al, 1994).
Hitherto, there have been no reports of a comparison of data
elicited with the two methods in SCCHN. The aim of the present
study was to compare DNA FCM and cytogenetics in SCCHN and
to assess the applicability ofthe methods in clinical work.
MATERIALS AND METHODS
Tumour sampling
Tumour samples were obtained from diagnostic biopsies or at
surgery from October 1990 to the end of February 1994. All
samples were divided into three parts: one for histopathological
examination, one for storage at -70°C in dimethyl sulphoxide
citrate buffer (DMSO) before FCM and one for cytogenetic
analysis.
1082Complexkaryotypes in diploidheadandneck SCC 1083
Tumour characteristics
One hundred and four samples from patients with SCCHN were
analysed with FCM and cytogenetic banding techniques. Ofthese,
31 yielded no karyotype information because ofeither infection or
poor growth in cell culture. Thus, a total of 73 samples were
successfully analysed with both techniques. All but two of the
patients had primary, untreated tumours.
Five sites were represented: oral cavity in 27 cases, oropharynx
in 14, hypopharynx in seven, larynx in 19, skin in three and nasal
cavity, lymph node ofunknown origin and oesophagus in one case
each. Of the 67 patients with tumours at one ofthe first four sites,
31 (46%) manifested lymph node metastasis at diagnosis. The
TNM distribution is shown in Table 1. The tumours were classi-
fied according to the International Union Against Cancer criteria
(Hermanek et al, 1987).
Cytogenetic analysis
The samples were processed as described earlier (Jin et al, 1993).
In brief, the fresh tumour samples were minced, disaggregated
overnight in collagenase and plated onto collagen-coated chamber
slides in a chemically defined, serum-free medium. The in situ
preparations were harvested after 5-10 days. G-banding was
obtained with Wright's stain. Clonality criteria and chromosome
abnormalities were defined according to the International System
for Human Cytogenetic Nomenclature (ISCN, 1991).
The karyotypes were divided into four groups: normal karyo-
type, numerical changes only, simple structural changes (one to
three changes) or complex structural changes (more than three
changes).
Chromosome index (CI) was defined as the quotient ofthe mean
chromosome number divided by 46.
FCM
The FCM procedure used (Wennerberg et al, 1996) was a modifi-
cation of that previously described (Tribukait et al, 1975;
Vindelov, 1977). In brief, the tumour samples were processed by a
combined mechanical, enzymatic and detergent procedure to
obtain nuclear suspension. The nuclear DNA was incubated in a
solution containing 50 ig ml-' propidium iodide (PI) and 0.6%
detergent (Nonidet P40) dissolved in Tris buffer. Analysis was
performed in a Cytofluorograph System 50-H (Ortho Instruments,
Westwood, MA, USA). Approximately 10 000-20 000 nuclei
were analysed in each sample. Cell doublets were excluded by
electronic threshold settings (Baldetorp et al, 1989).
Ploidy status was classified on DNA histograms as follows: one
single GO/GI peak, diploid; two or more peaks, non-diploid
(Hiddemann et al, 1984). The DNA Index (DI) for the non-diplod
stemline was calculated as the ratio between its GO/GI peak posi-
tion and the diploid peak position in the same histogram. DI forthe
diploid stemline was defined as 1.00. Histograms with at least
three stemlines were classified as multiploid.
The S-phase fraction (Spf) was calculated using a planimetric
method, assuming the fluorescence intensity values between GJG,
and G2 peaks to represent DNA-synthesizing cells that are rectan-
gularly distributed (Baisch et al, 1975).
In all cases, the width of the GJ1G, peak was determined in
terms ofthe coefficient of variation (CV) calculated at the base of
the diploid GJG, peak in the DNA histogram, and asymmetry of
the GO/GI peak was determined in terms of skewness assessed
independently by two observers (JA and BB). Both of these vari-
ables are considered to reflect the presence of small near-diploid
cell populations (Mandahl et al, 1993).
Debris was defined as signals from PI-stained chromatin frag-
ments derived from destroyed nuclei detected by FCM and that
appeared as events below the diploidGJG1 peak.
Statistical analysis
Statistical analysis of the data was performed with True Epistat
software (Epistat services, Richardson, TX, USA). Student's t-test
was used to investigate differences between Spf and CV values in
different subgroups. The Mann-Whitney test was used to evaluate
differences between DI and CI values in different subgroups. Chi-
square and Fischer's exact test were used when comparing cyto-
genetic and FCM data, as well as when comparing ploidy status
in different subgroups.
RESULTS
The distribution of karyotypes, CI, DI, CV and Spf is shown in
Table 1. Ofthe 73 tumours in the series as a whole, 52 (71%) were
diploid according to cytogenetic analysis and 24 (33%) diploid
according to FCM. Ofthe latter subgroup, 33% (8 out of24) had a
complex karyotype by cytogenetic analysis (Table 2), three ofthem
being hypodiploid (Figure 1), two non-diploid and the remaining
three pseudodiploid, manifesting complex structural rearrange-
ments (including 11q13 rearrangements in one case) (Table 3).
Ploidy status (Dl vs Cl)
In the subgroup of concordant cases (i.e., non-diploid by both
techniques), DI was consistently higher than CI in the series as a
whole as well as in a subgroup of oral tumours (both groups
P = 0.01). The results of linear regression analysis of the data in
this subgroup are presented in Figure 2 (y = 1.12x). Ofthe tumours
that were non-diploid according to FCM, 67% (33 out of49) were
diploid according to cytogenetic analysis. However, cytogeneti-
cally diploid and non-diploid subgroups did not differ in median
DI (1.76 vs 1.81; P = 0.48). All five tumours that were multiploid
according to FCM had a normal karyotype.
Spf
The mean Spfamong tumours with measurable values (n = 70) was
16.4% (Table 1). The mean Spfwas higher in the'FCM non-diploid
than in the FCM diploid subgroup (18.1% vs 13.1%; P=0.001).
The total number ofcells in the S-phase region was calculated from
the mid-S-phase area, and then divided by the total number ofcells.
As in diploid tumours a fraction of normal stromal cells may be
included in the denominator, the Spfvalue for diploid tumours may
be falsely lower than that for non-diploid tumours. There was no
significant difference in mean Spf between cytogenetically
non-diploid and diploid/hypodiploid tumours (16.3% vs 16.5%).
There was no correlation between tumour karyotype and Spf.
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Table 1. Distribution of TNM status, site, karyotype, chromosome index, DNA index, coefficient of variation and S-phase fraction in 73 cases of SCCHN
Case no. TNM Site Karyotype CI DIa Dib CV Spf Comments
300 Tongue
310 Oropharynx
200 Floor of mouth
410 Floor of mouth
300 Larynx
400 Trig. retromol.
200 Oropharynx
300 Oropharynx
420 Oropharynx
320 Oropharynx
400 Larynx
210 Skin
200 Tongue
100 Trig. retromol.
X20 Lymph node
200 Hypopharynx
400 Larynx
200 Larynx
200 Larynx
301 Hypopharynx
320 Hypopharynx
420 Floor of mouth
410 Hypopharynx
200 Larynx
100 Larynx
420 Oropharynx
100 Gingiva
120 Hypopharynx
300 Tongue
220 Soft palate
xxx Skin (ear)
220 Hypopharynx
400 Bucca
200 Larynx
421 Gingiva
100 Larynx
200 Larynx
320 Trig. retromol.
300 Larynx
400 Gingiva
400 Tonsil
200 Larynx
300 Tonsil
420 Tongue
330 Tonsil
XXX Skin (ear)
120 Larynx
320 Floor of mouth
200 Tongue
330 Tongue
110 Tongue
220 Tongue
410 Gingiva
200 Larynx
220 Tongue
400 Larynx
400 Gingiva
410 Larynx
210 Tonsil
200 Larynx
330 Floor of mouth
420 Floor of mouth
400 Larynx
120 Tonsil
200 Oral cavity
400 Larynx
110 Tonsil
XXX Nasal cavity
310 Tongue
47,+X
74-79,cx
78-88,cx
N
63-67,cx
45,cx
45,-Y/47,+7/47,+Y
N
63-66,cx
45,-Y
82,cx
N
45,-Y/47,+Y
N
N
N
N
N
N
45,-Y
69-72,cx
66-69,cx
45,-Y
46,cx
N
68-72,cx
45,-Y
46,s
47,cx
72-79,cx
45,-Y
N
42-45,cx
46,cx
N
45,-Y,s
N
45,-Y
45,-Y
50-54,cx
N
N
43,cx
76-87,cx
N
N
N
N
N/72-82,cx
73-77,cx
N
N
N
N
N
N
N
N
70,cx
60-70,cx
N
47,+Y
46,s
N
38-44,cx
73,cx
N
N
40-44,cx/45,cx
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2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
1.02
1.66
1.80
1.00
1.42
0.98
1.00
1.00
1.40
0.98
1.78
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
0.98
1.53
1.46
0.98
1.00
1.00
1.52
0.98
1.00
1.02
1.64
0.98
1.00
0.94
1.00
1.00
0.98
1.00
0.98
0.98
1.14
1.00
1.00
0.93
1.77
1.00
1.00
1.00
1.00
1.67
1.63
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.52
1.41
1.00
1.02
1.00
1.00
0.90
1.59
1.00
1.00
0.93
1.00
2.03
1.98
1.49
1.57
1.86
1.00
1.36
1.74
2.41
1.86
1.00
1.87
1.00
1.53
1.58
1.00
2.00
1.00
1.00
1.67
1.81
1.00
1.00
1.00
1.00
1.44
1.00
1.00
1.00
1.95
1.79
1.00
1.00
1.56
1.56
1.83
1.00
1.76
1.52
1.98
1.75
1.00
1.95
1.00
1.00
1.97
1.48
1.98
1.85
1.58
1.00
1.88
1.58
1.98
1.67
1.08
1.91
1.55
1.76
1.73
1.87
1.70
1.00
1.94
1.14
1.21
1.93
1.00
3.01
2.43
1.90
1.59
2.19
2.34
4.4
6.2
11.7
5.6
5.9
5.8
7.2
5.5
4.9
6.4
5.4
13.6
4.6
4.1
6.6
3.8
12.9
5.7
7.0
4.7
6.0
3.5
9.7
6.0
4.2
4.3
5.5
4.3
5.1
6.1
3.9
4.3
4.6
5.9
9.7
3.9
6.1
9.1
4.8
4.1
4.8
4.4
6.3
3.1
3.7
3.4
4.9
3.8
4.9
4.8
3.9
3.3
3.4
4.7
3.5
4.2
2.9
7.0
3.5
3.8
4.0
3.2
4.2
3.3
4.0
3.7
4.2
13
20
19
25
15
16
25
15
12
32
8
18
13
9
18
24
7
18
9
27
18
13
12
10
18
23
18
12
15
11
15
12
21
14
12
17
22
18
17
10
12
15
10
21
21
21
16
23
9
13
12
13
21
13
20
10
16
16
14
39
13
18
6
23
14
10
' Deb
Rec
Skew
Deb
Rec, Deb, Skew
Skew
Deb
Deb
Deb
Skew
Deb
Skew
Skew
Deb
Deb
Rec
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Table 1. Cont'd
Case no. TNM Site Karyotype CI DIP Dlb CV Spf Comments
70 200 Tonsil N 1.00 1.00 - 3.5 10
71 220 Hypopharynx N 1.00 1.79 - 2.6 28
72 220 Floor of mouth 77-83,cx 1.74 2.06 - 8.5 22
73 XXX Oesophagus 45,-Y/47,+Y 1.00 1.70 - 5.0 22
aDI, DNA index. bDI, DNA index in an extra non-diploid population, Cl, chromsome index; CV, coefficient of variation in the diploid population; Spf, S-phase
fraction; Deb, debris . (high background contribution); Rec, recurrent disease; Skew, skewness of the G/G1 peak; N, normal karyotype; cx, complex karyotype
(more than three structural changes); s, simple structural rearrangements (one to three structural changes).
Table 2 Ploidy status according to FCM and karyotypic findings in 73 cases
of SCCHN
Ploidy status by FCM
Karyotype Diploid Non-diploid
N 11 23
Num/S 5 9
Cx 8 17
Eight (33%) of 24 flow cytometrically diploid tumours had complex
karyotypes. N, normal karyotype; Num, numerical changes only; S, simple
structural changes; Cx, complex karyotype.
CV and skewness
The mean CV among tumours with measurable values was 5.3,
both for the series as a whole (n = 71) and for the subgroup of
tumours diploid according to FCM (n = 23). There was no correla-
tion between CV and any cytogenetic subgroup. In the subgroup
diploid according to FCM, 88% (seven out of eight) of tumours
with complex karyotype had CV values below the mean value. A
skewed GO/GI peak was yielded by five tumours, four of which
were diploid according to FCM, but only one of these four
tumours had a complex karyotype.
Unsuccessful karyotypes
Of the 31 tumours from which no karyotypes could be obtained,
13 (42%) were diploid according to FCM, with a mean Spfof 13.6
and a mean CV of 5.5. Either the CV values or the ploidy status
differed from corresponding results in the study group (P = 0.56
and P = 0.51 respectively). Furthermore, for either diploid or non-
diploid tumours, the Spf values differed between the two groups
(P = 0.22 and P = 0.10 respectively).
DISCUSSION
A possible explanation of the poor prognostic value of FCM
results in cases of SCCHN was yielded by the present study, in
which chromosomal changes associated with aggressive tumour
growth were found to occur unaccompanied by changes in tumour
DNA content. Of 24 tumours diploid according to FCM, eight
(33%) had complex karyotypes according to cytogenetic analysis
(Table 3). Three of these eight cases were cytogenetically diploid
(CI 1.00-1.02). One of these cases (no. 34) showed 11q13
rearrangements. A complex karyotype, in general, and chromo-
somal abnormalities of 11q13, in particular, are correlated to poor
prognosis (Akervall et al, 1995). Another three of the eight
Table 3 Three flow cytometrically diploid tumours manifesting complex
structural rearrangements at cytogenetic analysis
Case
no. Site Karyotype Cl Dl
24 Larynx 46, XY, der(5)t(5;10)(q13;q11), 1.00 1.00
i(7)(q1O), der(10)t(7;10)(p11;q11),
der(15)t(5;15)(q13;p13)(3)
29 Tongue 47, XY, t(1;22)(q21;p13), i(3)(q1O), 1.02 1.00
del(4)(q28), +i(7)(plO), i(8)(q1O)(14)
34 Larynx 46,XY, del(1)(q42), add(4)(p16), del(9) 1.00 1.00
(q32), t(9;11)(q22;q13), add(10)(q26),
add(17)(q25)(7)/46, XY, del(1)(q42),
t(1;14)(q25;q22), der(6)t(6;16)(p21;q22),
add(12)(p12), der(16)add(16)(p12)t(6;16),
add(17)(q11), der(17)t(16; 17)(q12-13;
qll-21) add(17)(pll), add(19)(q13)
11q13 rearrangements in bold type.
tumours diploid according to FCM were found to be hypodiploid
at cytogenetic analysis (Table 1 cases 33, 43 and 69; Figure 1). As
no internal control can be included in the present FCM preparation
technique, hypodiploidy is not applicable, and the first stemline
peak appearing to the left in the histogram should be regarded as
the diploid (Hiddemann et al, 1984). However, in other cancer
types, e.g. breast cancer, hypodiploidy has been associated with
poor prognosis (Ferno et al, 1992a). To our knowledge, no such
relationship has been reported for SCCHN. Finally, two of the
eight FCM diploid tumours ofcomplex karyotypes (Table 1 cases
26 and 30) were non-diploid according to cytogenetic analysis.
There are several possible reasons why these non-diploid cell
populations were not detected by FCM. First, as no bimodality (i.e.
two GJG, peaks close together) was seen, nuclei might have been
severely maltreated in the preparation procedure for FCM.
Second, the cytogenetically detected clone might have been too
small to be detected by FCM. Third, it is possible that the tumours
were genetically heterogeneous. Intratumour heterogeneity in
FCM results has been reported for other tumour types (Ferno et al,
1992b), a finding in accord with findings in SCCHN in our group
(data not shown).
The CV value reflects the width of the G/G1 peak, enabling a
more thorough subclassification of the peak. In FCM diploid
tumours other than SCCHN, the prognostic value of FCM has
been suggested to be enhanced by the use of the CV approach,
which enables small near-diploid populations with aggressive
biological potential to be identified (Mandahl et al, 1993;
Gustafson, 1994). However, this suggestion derives no support
from the results of the present study as seven of the eight FCM
diploid tumours with complex karyotypes had low CV values.
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Of 49 tumours non-diploid according to FCM, 34 (69%) were
shown by cytogenetic analysis to have diploid DNA content.
Similar findings have been reported for other solid tumours (El-
Naggar and Pathak, 1992; Breitkreutz et al, 1993). These findings
support the hypothesis that certain non-diploid stemlines are diffi-
cult to grow in short-term cell culture, whereas certain diploid
clones have a selective growth advantage. These 34 tumours did
not differ in DNA content from the 15 tumours non-diploid
Figure 1 Case no. 69 (Table 1). A40-year-dd man with recumrrnt SCCHN of
thetongue, clasfed asT3N1MO, with (A)-a-complex hypodpoid karyope:
40-44, XY dlc(1;11)(qlO;pII), der(3;19)(qlO;qlO), ins(4;?)(p14;?), i(6)(pl0),
i(6)(q10), ..de4(6q15), 1(8)(qlO), -11, der(13;14)(qlO;qlO), del(16)(q13), -17,
-18, -19, -21, der(?)t(?:1)(?;p22), + 1-2mar(arrowheds idicte brealponts
in clonal rearrngemerfts; lossofchromosome 15 and rearrangementof one
chromosome 21 were non-clonal), and Badiploid histogram by FCM
according to both techniques, indicating that the grade of non-
diploidy is not responsible for lack of outgrowth in in vitro cell
culture. Furthermore, the 34 cases clearly show that there are
diploid tumour clones present in FCM non-diploid tumours, i.e.,
theGJG, peak in these cases does notonly consistofstromal cells.
In the present study, DI values were consistently higher than CI
values (Figure 2), a finding similar to those previously reported by
others (Smeets et al, 1987; Remvikos et al, 1988b; Dressler et al,
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2.2
2.0
1.8
x
v 1.6
z
D 1.4
y=1.12x
1.2
1.2 1.4 1.6 1.8 2.0
Chromosome index (Cl)
Figure 2 Linear regression in 15 cases, non-diploid by both FCM and
cytogenetics (y = 1.12x). Systematically higher Dl than Cl are seen
1993; Mandahl et al, 1993). There are several possible cytogenetic
explanations for this. Chromosomes may be lost during the hypo-
tonic treatment used to obtain good chromosome spread, or iflarge
chromosomes (e.g. chromosomes 1 or 2) are preferentially gained,
the DI will be proportionally higher than the CI, which is based on
the number ofchromosomes and not on their size.
The high rate ofunsuccessful cytogenetic analysis in the present
investigation (30%) is similar to figures reported for our previous
studies (Jin et al, 1993). From a clinical point of view, this is a
major drawback with regard to the applicability of the method to
yield prognostic information in SCCHN. Furthermore, if it turns
out that some of the cell populations with simple karyotypic
changes, e.g. gain or loss of a single chromosome or one or a few
balanced structural rearrangements, as the sole anomalies are not
representative of the tumour parenchyma, the success rate would
be even lower (25 out of73, 34%).
Furthermore, the present study indicates that DNA ploidy status
by FCM provides information of the genetic changes in SCCHN
that is too unspecific to be used as a reliable prognostic marker.
Possibly, further investigations of Spfcould improve this aspect.
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